185 related articles for article (PubMed ID: 37632456)
1. CGMP Compliant Microfluidic Transfection of Induced Pluripotent Stem Cells for CRISPR-Mediated Genome Editing.
Bohrer LR; Stone NE; Wright AT; Han S; Sicher I; Sulchek TA; Mullins RF; Tucker BA
Stem Cells; 2023 Nov; 41(11):1037-1046. PubMed ID: 37632456
[TBL] [Abstract][Full Text] [Related]
2. Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration.
Burnight ER; Gupta M; Wiley LA; Anfinson KR; Tran A; Triboulet R; Hoffmann JM; Klaahsen DL; Andorf JL; Jiao C; Sohn EH; Adur MK; Ross JW; Mullins RF; Daley GQ; Schlaeger TM; Stone EM; Tucker BA
Mol Ther; 2017 Sep; 25(9):1999-2013. PubMed ID: 28619647
[TBL] [Abstract][Full Text] [Related]
3. Correction of Hemoglobin E/Beta-Thalassemia Patient-Derived iPSCs Using CRISPR/Cas9.
Wattanapanitch M
Methods Mol Biol; 2021; 2211():193-211. PubMed ID: 33336279
[TBL] [Abstract][Full Text] [Related]
4. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
[TBL] [Abstract][Full Text] [Related]
5. Correction of NR2E3 Associated Enhanced S-cone Syndrome Patient-specific iPSCs using CRISPR-Cas9.
Bohrer LR; Wiley LA; Burnight ER; Cooke JA; Giacalone JC; Anfinson KR; Andorf JL; Mullins RF; Stone EM; Tucker BA
Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 30959774
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9-Based Genome Editing of Human Induced Pluripotent Stem Cells.
Giacalone JC; Sharma TP; Burnight ER; Fingert JF; Mullins RF; Stone EM; Tucker BA
Curr Protoc Stem Cell Biol; 2018 Feb; 44():5B.7.1-5B.7.22. PubMed ID: 29512106
[TBL] [Abstract][Full Text] [Related]
7. A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells.
Geng BC; Choi KH; Wang SZ; Chen P; Pan XD; Dong NG; Ko JK; Zhu H
Acta Pharmacol Sin; 2020 Nov; 41(11):1427-1432. PubMed ID: 32555510
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9 Genome Editing of Human-Induced Pluripotent Stem Cells Followed by Granulocytic Differentiation.
Dannenmann B; Nasri M; Welte K; Skokowa J
Methods Mol Biol; 2020; 2115():471-483. PubMed ID: 32006418
[TBL] [Abstract][Full Text] [Related]
9. Efficient Gene Editing of Human Induced Pluripotent Stem Cells Using CRISPR/Cas9.
Yumlu S; Bashir S; Stumm J; Kühn R
Methods Mol Biol; 2019; 1961():137-151. PubMed ID: 30912045
[TBL] [Abstract][Full Text] [Related]
10. Genome Editing of Induced Pluripotent Stem Cells Using CRISPR/Cas9 Ribonucleoprotein Complexes to Model Genetic Ocular Diseases.
Getachew H; Chinchilla B; Fernandez-Godino R
Methods Mol Biol; 2022; 2549():321-334. PubMed ID: 34128206
[TBL] [Abstract][Full Text] [Related]
11. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
[TBL] [Abstract][Full Text] [Related]
12. Highly efficient genome editing via CRISPR-Cas9 in human pluripotent stem cells is achieved by transient BCL-XL overexpression.
Li XL; Li GH; Fu J; Fu YW; Zhang L; Chen W; Arakaki C; Zhang JP; Wen W; Zhao M; Chen WV; Botimer GD; Baylink D; Aranda L; Choi H; Bechar R; Talbot P; Sun CK; Cheng T; Zhang XB
Nucleic Acids Res; 2018 Nov; 46(19):10195-10215. PubMed ID: 30239926
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration.
Burnight ER; Giacalone JC; Cooke JA; Thompson JR; Bohrer LR; Chirco KR; Drack AV; Fingert JH; Worthington KS; Wiley LA; Mullins RF; Stone EM; Tucker BA
Prog Retin Eye Res; 2018 Jul; 65():28-49. PubMed ID: 29578069
[TBL] [Abstract][Full Text] [Related]
14. Efficient, footprint-free human iPSC genome editing by consolidation of Cas9/CRISPR and piggyBac technologies.
Wang G; Yang L; Grishin D; Rios X; Ye LY; Hu Y; Li K; Zhang D; Church GM; Pu WT
Nat Protoc; 2017 Jan; 12(1):88-103. PubMed ID: 27929521
[TBL] [Abstract][Full Text] [Related]
15. CRISPR Base Editing in Induced Pluripotent Stem Cells.
Chang YJ; Xu CL; Cui X; Bassuk AG; Mahajan VB; Tsai YT; Tsang SH
Methods Mol Biol; 2019; 2045():337-346. PubMed ID: 31250381
[TBL] [Abstract][Full Text] [Related]
16. Genome Editing in Human Induced Pluripotent Stem Cells (hiPSCs).
Higo S; Hikoso S; Miyagawa S; Sakata Y
Methods Mol Biol; 2021; 2320():235-245. PubMed ID: 34302662
[TBL] [Abstract][Full Text] [Related]
17. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system.
Wattanapanitch M; Damkham N; Potirat P; Trakarnsanga K; Janan M; U-Pratya Y; Kheolamai P; Klincumhom N; Issaragrisil S
Stem Cell Res Ther; 2018 Feb; 9(1):46. PubMed ID: 29482624
[TBL] [Abstract][Full Text] [Related]
18. Carboxylated nanodiamond-mediated CRISPR-Cas9 delivery of human retinoschisis mutation into human iPSCs and mouse retina.
Yang TC; Chang CY; Yarmishyn AA; Mao YS; Yang YP; Wang ML; Hsu CC; Yang HY; Hwang DK; Chen SJ; Tsai ML; Lai YH; Tzeng Y; Chang CC; Chiou SH
Acta Biomater; 2020 Jan; 101():484-494. PubMed ID: 31672582
[TBL] [Abstract][Full Text] [Related]
19. Rescue of premature aging defects in Cockayne syndrome stem cells by CRISPR/Cas9-mediated gene correction.
Wang S; Min Z; Ji Q; Geng L; Su Y; Liu Z; Hu H; Wang L; Zhang W; Suzuiki K; Huang Y; Zhang P; Tang TS; Qu J; Yu Y; Liu GH; Qiao J
Protein Cell; 2020 Jan; 11(1):1-22. PubMed ID: 31037510
[TBL] [Abstract][Full Text] [Related]
20. Induced Pluripotent Stem Cells and Genome-Editing Tools in Determining Gene Function and Therapy for Inherited Retinal Disorders.
Benati D; Leung A; Perdigao P; Toulis V; van der Spuy J; Recchia A
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
